Association Between the Lymphocyte-to-high-density Lipoprotein Ratio and Metabolic Dysfunction-associated Steatotic Liver Disease Among US Adults: a Cross-sectional Study from NHANES 2017 to 2020

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2024 Dec 23

PMID 39716074

Authors

Chuanzhi Tang

Dadi Peng

Kezhen Zong

Zhongjun Wu

Miao Gong

Hui Li

Zuotian Huang

Shanshan Li

Affiliations

Soon will be listed here.

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a liver disease that is strongly associated with chronic low-grade inflammation. Stage 3 of MASLD is characterized by excessive formation of connective tissues, commonly referred to as liver fibrosis. Although numerous inflammatory markers have been identified and extensively studied, including the tumor necrosis factor-α and interleukin-6 have been studied [Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64], the lymphocyte-to-high-density lipoprotein ratio (LHR) as a new biomarker that has not been sufficiently studied. This study aims to investigate the relationship between LHR levels and MASLD, determine its potential as a predictive marker for steatosis and fibrosis stages.

Methods: This was a population-based study using data from 15,560 participants in the 2017-2020 National Health and Nutrition Examination Survey (NHANES) database. The study aimed to explore the relationship between LHR and MASLD. The disease progression was tracked by continuously measuring CAP and liver stiffness measurements. Participants who exhibited a median Controlled Attenuation Parameter (CAP) of 248 dB/m or higher were deemed to have hepatic steatosis. The LHR was calculated by dividing the lymphocyte count by the high-density lipoprotein cholesterol (HDL-C) level. Multivariate linear regression models were employed to explore the linear association between LHR and MASLD. Fitted smoothing curves and threshold effect analysis were employed to display nonlinear relationships. A two-part linear regression model was employed to estimate threshold effects. Subgroup analyses were conducted to determine the consistency of this association across various demographic groups.

Results: A total of 6,950 adults aged 18 years and older were enrolled in the study, with an average age of 48.15 ± 17.10 years (49.14% male, 50.86% female). The adjusted multiple logistic regression analysis revealed a significant positive correlation between LHR and MASLD (OR: 1.64, 95% CI: 1.40-1.92). Using the complex two-piece linear regression model, we observed an inverted L-shaped association between LHR and CAP, suggesting a critical inflection point at -2.58. Subgroup analyses indicated a pronounced association of the LHR index with obese individuals (OR: 1.96, 95% CI: 1.66-2.32) and females (OR: 1.76, 95% CI: 1.25-2.46). There was no significant association between LHR and clinically significant fibrosis.

Conclusion: The LHR index is positively correlated with MASLD among US adults. Therefore, LHR may be a robust marker for early screening, diagnosis, and monitoring of treatment efficacy in clinical practice.

References

Akboga M, Canpolat U, Yuksel M, Yayla C, Yilmaz S, Turak O . Platelet to lymphocyte ratio as a novel indicator of inflammation is correlated with the severity of metabolic syndrome: A single center large-scale study. Platelets. 2015; 27(2):178-83. DOI: 10.3109/09537104.2015.1064518. View

Younossi Z . Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2018; 70(3):531-544. DOI: 10.1016/j.jhep.2018.10.033. View

Ji Y, Yin Y, Li Z, Zhang W . Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients. 2019; 11(8). PMC: 6724003. DOI: 10.3390/nu11081712. View

Vilar-Gomez E, Nephew L, Vuppalanchi R, Gawrieh S, Mladenovic A, Pike F . High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology. 2021; 75(6):1491-1506. DOI: 10.1002/hep.32207. View

Stefano J, Duarte S, Ribeiro Leite Altikes R, Oliveira C . Non-pharmacological management options for MAFLD: a practical guide. Ther Adv Endocrinol Metab. 2023; 14:20420188231160394. PMC: 10031614. DOI: 10.1177/20420188231160394. View

Byrne C, Targher G . NAFLD: a multisystem disease. J Hepatol. 2015; 62(1 Suppl):S47-64. DOI: 10.1016/j.jhep.2014.12.012. View

de Oliveira S, Houseright R, Graves A, Golenberg N, Korte B, Miskolci V . Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. J Hepatol. 2018; 70(4):710-721. PMC: 6436385. DOI: 10.1016/j.jhep.2018.11.034. View

Siddiqui M, Vuppalanchi R, Van Natta M, Hallinan E, Kowdley K, Abdelmalek M . Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2018; 17(1):156-163.e2. PMC: 6203668. DOI: 10.1016/j.cgh.2018.04.043. View

Xie R, Xiao M, Li L, Ma N, Liu M, Huang X . Association between SII and hepatic steatosis and liver fibrosis: A population-based study. Front Immunol. 2022; 13:925690. PMC: 9520084. DOI: 10.3389/fimmu.2022.925690. View

10.

Wong V, Adams L, de Ledinghen V, Wong G, Sookoian S . Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018; 15(8):461-478. DOI: 10.1038/s41575-018-0014-9. View

11.

Myint M, Oppedisano F, De Giorgi V, Kim B, Marincola F, Alter H . Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions. J Transl Med. 2023; 21(1):757. PMC: 10605416. DOI: 10.1186/s12967-023-04627-0. View

12.

Curtin L, Mohadjer L, Dohrmann S, Montaquila J, Kruszan-Moran D, Mirel L . The National Health and Nutrition Examination Survey: Sample Design, 1999-2006. Vital Health Stat 2. 2012; (155):1-39. View

13.

Targher G, Byrne C, Tilg H . NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020; 69(9):1691-1705. DOI: 10.1136/gutjnl-2020-320622. View

14.

Tapper E, Loomba R . Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nat Rev Gastroenterol Hepatol. 2018; 15(5):274-282. PMC: 7504909. DOI: 10.1038/nrgastro.2018.10. View

15.

Sheka A, Adeyi O, Thompson J, Hameed B, Crawford P, Ikramuddin S . Nonalcoholic Steatohepatitis: A Review. JAMA. 2020; 323(12):1175-1183. DOI: 10.1001/jama.2020.2298. View

16.

Kim D, Kim W, Kim H, Therneau T . Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2012; 57(4):1357-65. PMC: 3622816. DOI: 10.1002/hep.26156. View

17.

Lu Y, Xu X, Wu J, Ji L, Huang H, Chen M . Association between neutrophil-to-high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in the US population: a nationally representative cross-sectional study using NHANES data.... BMC Gastroenterol. 2024; 24(1):300. PMC: 11378436. DOI: 10.1186/s12876-024-03394-6. View

18.

Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than T . Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019; 70(4):1457-1469. PMC: 6766425. DOI: 10.1002/hep.30626. View

19.

Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C . Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Clin Gastroenterol Hepatol. 2019; 17(11):2310-2319.e6. DOI: 10.1016/j.cgh.2019.01.027. View

20.

Wakabayashi I, Sotoda Y, Hirooka S, Orita H . Association between cardiometabolic index and atherosclerotic progression in patients with peripheral arterial disease. Clin Chim Acta. 2015; 446:231-6. DOI: 10.1016/j.cca.2015.04.020. View